237 related articles for article (PubMed ID: 16266359)
41. The use of lidocaine patches.
Weil AB; Ko J; Inoue T
Compend Contin Educ Vet; 2007 Apr; 29(4):208-10, 212, 214-6. PubMed ID: 17726850
[TBL] [Abstract][Full Text] [Related]
42. [Localized neuropathic pain--5% lidocaine medicated patch as a first-line treatment and as add-on therapy: literature review and personal experience].
Casale R; Polati E; Schweiger V; Coluzzi F; Bhaskar A; Consalvo M
Minerva Med; 2014 Jun; 105(3):177-95. PubMed ID: 24988084
[TBL] [Abstract][Full Text] [Related]
43. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of high concentration lidocaine for trigeminal nerve block in patients with trigeminal neuralgia.
Han KR; Kim C; Chae YJ; Kim DW
Int J Clin Pract; 2008 Feb; 62(2):248-54. PubMed ID: 18036166
[TBL] [Abstract][Full Text] [Related]
45. Strategies for the diagnosis and treatment of neuropathic pain secondary to diabetic peripheral sensory polyneuropathy.
Guastella V; Mick G
Diabetes Metab; 2009 Feb; 35(1):12-9. PubMed ID: 19046917
[TBL] [Abstract][Full Text] [Related]
46. A novel needle-free powder lidocaine delivery system for rapid local analgesia.
Zempsky WT; Robbins B; Richards PT; Leong MS; Schechter NL
J Pediatr; 2008 Mar; 152(3):405-11. PubMed ID: 18280850
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study.
Meier T; Wasner G; Faust M; Kuntzer T; Ochsner F; Hueppe M; Bogousslavsky J; Baron R
Pain; 2003 Nov; 106(1-2):151-8. PubMed ID: 14581122
[TBL] [Abstract][Full Text] [Related]
48. 5% lidocaine medicated plaster use in children with neuropathic pain from burn sequelae.
Orellana Silva M; Yañez V; Hidalgo G; Valenzuela F; Saavedra R
Pain Med; 2013 Mar; 14(3):422-9. PubMed ID: 23279572
[TBL] [Abstract][Full Text] [Related]
49. Lidocaine 2% gel versus plain lubricating gel for pain reduction during flexible cystoscopy: a meta-analysis of prospective, randomized, controlled trials.
Patel AR; Jones JS; Babineau D
J Urol; 2008 Mar; 179(3):986-90. PubMed ID: 18206920
[TBL] [Abstract][Full Text] [Related]
50. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study.
Devers A; Galer BS
Clin J Pain; 2000 Sep; 16(3):205-8. PubMed ID: 11014393
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness of a heated lidocaine/tetracaine topical patch for pain associated with myofascial trigger points: results of an open-label pilot study.
Rauck R; Busch M; Marriott T
Pain Pract; 2013 Sep; 13(7):533-8. PubMed ID: 23231060
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of anesthetic agents during peripheral intravenous cannulation in the pediatric emergency department.
Pershad J; Steinberg SC; Waters TM
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):952-61. PubMed ID: 18838648
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and Tolerance of Lidocaine 5% Patches in Neuropathic Pain and Pain Related to Vaso-occlusive Sickle Cell Crises in Children: A Prospective Multicenter Clinical Study.
Rousseau V; Morelle M; Arriuberge C; Darnis S; Chabaud S; Launay V; Thouvenin S; Roumenoff-Turcant F; Metzger S; Tourniaire B; Marec-Berard P
Pain Pract; 2018 Jul; 18(6):788-797. PubMed ID: 29266772
[TBL] [Abstract][Full Text] [Related]
54. Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial.
Shaibani A; Biton V; Rauck R; Koch B; Simpson J
Eur J Pain; 2009 May; 13(5):458-63. PubMed ID: 18619874
[TBL] [Abstract][Full Text] [Related]
55. Warm lidocaine/tetracaine patch versus placebo before pediatric intravenous cannulation: a randomized controlled trial.
Singer AJ; Taira BR; Chisena EN; Gupta N; Chipley J
Ann Emerg Med; 2008 Jul; 52(1):41-7. PubMed ID: 18395934
[TBL] [Abstract][Full Text] [Related]
56. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
57. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine.
Viola V; Newnham HH; Simpson RW
J Diabetes Complications; 2006; 20(1):34-9. PubMed ID: 16389165
[TBL] [Abstract][Full Text] [Related]
58. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy.
Niermeijer JM; Eurelings M; van der Linden MW; Lokhorst HM; Franssen H; Fischer K; Teunissen LL; van den Berg LH; Schobben F; Wokke JH; Notermans NC
Neurology; 2007 Jul; 69(1):50-9. PubMed ID: 17606880
[TBL] [Abstract][Full Text] [Related]
59. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial).
Altman RD; Rosen JE; Bloch DA; Hatoum HT; Korner P
Semin Arthritis Rheum; 2009 Aug; 39(1):1-9. PubMed ID: 19539353
[TBL] [Abstract][Full Text] [Related]
60. Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study.
Gimbel J; Linn R; Hale M; Nicholson B
Am J Ther; 2005; 12(4):311-9. PubMed ID: 16041194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
